Capital Markets Event: View a recording and access materials presented at OXB’s Capital Markets Event held on 2nd June 2026.

VectorXcellerator: OXB has selected the first programmes to move forward through VectorXcellerator, supporting earlier collaboration in advanced therapies.

OXB launches fast-track offering for AAV and lentiviral vector platforms, accelerating viral vector development and manufacture.

News: OXB honoured at 2025 CDMO Leadership Awards Europe in ‘Cell & Gene Therapy’ category.

Webinar: Optimising viral vector manufacturing with CDMO expertise and innovation

Location: Virtual Start Date: 18th Nov, 2025
Event Website: https://www.fiercebiotech.com/premium/webinar/1373769 Details: 10:00 am EST / 4:00 pm CET

Webinar: Optimising viral vector manufacturing with CDMO expertise and innovation

Webinar with Fierce Biotech

What will you learn about during this webinar?

  • Cutting-edge innovation technologies improving vector purity and productivity
  • A CDMO platform approach ensuring seamless integration of technologies and processes to drive performance
  • A rapid development of vector genome titre and gene expression assays within just 2 months

Speaker:
Sébastien Ribault, PhD, Chief Business Officer, OXB